Ocugen
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
11 Great Valley Pkwy, Malvern, Pennsylva...Phone Number
(484) 328-4701Website
www.ocugen.comRevenue
<$5 MillionStock Symbol
OCGNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Ocugen
Ocugen is a clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative therapies for rare and underserved eye diseases. The company specializes in ophthalmology research and is advancing a pipeline that includes gene therapies, biologic treatments, and other therapeutic technologies designed to address retinal and ocular surface disorders. Its research programs aim to develop novel solutions for conditions that currently have limited treatment options, with a particular emphasis on inherited retinal diseases and other vision-related disorders. Through scientific research, clinical development, and strategic collaborations, Ocugen works to bring new therapeutic approaches to patients while contributing to advancements in genetic and regenerative medicine within the ophthalmology field.Explore more
Ocugen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ocugen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Ocugen is spiking on competitors!
Product Launch: Get notified when Ocugen launches new products
Ocugen, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ocugen recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Ocugen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ocugen
Funding: Get notified immidiatlly once Ocugen has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ocugen has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ocugen
Compare insights from companies similar to Ocugen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ocugen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ocugen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ocugen.
Ocugen financials insights
Gather financial insights about Ocugen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$6M
2017
Series B
$7.5M
2020
Debt
$350K
2021
Stock Offering
$23M
2024
Debt
$30M
Ocugen Tech Stack
A closer look at the technologies used by Ocugen
See more technologies
Most Recent Scoops
Open Position
Person-Based
Project
Ocugen has advanced OCU410ST, a novel modifier gene therapy program for Stargardt disease an inherited retinal disease with no approved treatment globally becoming the first company to pursue this approach for the condition, which affects approximately 100,000 patients in the U.S. and EU combined, and has received a Rare Pediatric Designation from the FDA for this program.
Medical Research, Pharmaceuticals
Project
Ocugen is accelerating all Azure tools including Fabric, SQL, Spark, and semantic-based, vector-based, and graph-based workloads with full GPU acceleration to enable faster response times for agentic AI systems and maximize token generation efficiency.
Cloud, Machine Learning, Artificial Intelligence
Project
Ocugen News & Media
Ocugen (OCGN) Q2 2026 Earnings Call Transcript
Gene therapy developer advances three Phase III programs toward 2028 regulatory filings.Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ETOcugen to Participate in Upcoming August Investor Conferences
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences in August 2026.Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 6, 2026.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ocugen
Sign Up For FreeTo access detailed company insights
Ocugen is a clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative therapies for rare and underserved eye diseases. The company specializes in ophthalmology research and is advancing a pipeline that includes gene therapies, biologic treatments, and other therapeutic technologies designed to address r... Read More
